Press Releases Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 10:25:00 13/03/2026 pm IST			5-day change	1st Jan Change
76.39 ^EUR	-0.17%		0.00%	-7.65%

11/03	Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit	RE
09/03	Global drugmakers rush to boost US presence as tariff threat looms	RE

Press Releases

13/03	Sanofi: Informations relatives au nombre de droits de vote et d'actions - FEVRIER 2026	PU
08/03	Brazil’s EMS buys Medley	AQ
05/03	Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director	GL
04/03	Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report	GL
02/03	Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease	AQ
02/03	Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment	AQ
02/03	Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease	GL
27/02	New sleeping sickness pill gets nod, paving the way for use in Africa	AQ
27/02	Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment	GL
27/02	Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness	GL
24/02	Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis	GL
17/02	Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report	GL
17/02	Sanofi announces leadership evolution in Specialty Care Business Unit	PR
17/02	Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease	GL
16/02	Sanofi - Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season	AQ
16/02	Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season	GL
12/02	Belén Garijo to become Chief Executive Officer of Sanofi	GL
11/02	Sanofi: Informations relatives au nombre de droits de vote et d'actions – JANVIER 2026	PU
10/02	EPO vs UPC: Inventive Step	AQ
10/02	Sanofi completes the acquisition of Dynavax	GL
10/02	Sanofi's rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia	AQ
09/02	Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia	GL
03/02	Sanofi announces the signing of a share buyback mandate for up to €1 billion	GL
02/02	Brazil in focus as Sanofi’s Medley draws bidders	AQ
02/02	Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease	GL